Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials

被引：0
|
作者：
Rashbaum, B. [1 ]
Lucasti, C. [2 ]
Mounzer, K. [3 ]
Melbourne, K. [4 ]
Kwon, P. [4 ]
Piontkowsky, D. [4 ]
机构：
[1] Capital Med Associates PC, Washington, DC USA
[2] South Jersey Infect Dis, Somers Point, NJ USA
[3] Philadelphia FIGHT, Philadelphia, PA USA
[4] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL THERAPY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P25
引用
收藏
页码：A44 / A45
页数：2
相关论文
共 50 条
  • [21] Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)
    Kulkarni, Rima
    Hodder, Sally L.
    Cao, Huyen
    Chang, Silvia
    Miller, Michael D.
    White, Kirsten L.
    HIV CLINICAL TRIALS, 2017, 18 (04): : 164 - 173
  • [22] Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
    Cid-Silva, Purificacion
    Fernandez-Bargiela, Noelia
    Margusino-Framinan, Luis
    Balboa-Barreiro, Vanesa
    Mena-De-Cea, Alvaro
    Lopez-Calvo, Soledad
    Vazquez-Rodriguez, Pilar
    Martin-Herranz, Isabel
    Miguez-Rey, Enrique
    Poveda, Eva
    Castro-Iglesias, Angeles
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (04) : 479 - 490
  • [23] A Review of the Efficacy and Safety of Genvoya (R) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection
    Angione, Sara A.
    Cherian, Sibyl M.
    Ozdener, Ayse Elif
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 216 - 221
  • [24] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
    Al Soub, Hussam
    Al-khal, A. Latif M.
    Alsoub, Deema
    Awouda, Waleed
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2020, 2020
  • [25] Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data
    Tabak, Fehmi
    Zerdali, Esra
    Altuntas, Ozlem
    Gunduz, Alper
    Bolukcu, Sibel
    Mete, Bilgul
    Nakir, Inci Y.
    Kumbasar Karaosmanoglu, Hayat
    Yildiz, Dilek S.
    Meric Koc, Meliha
    Dokmetas, Ilyas
    INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (06) : 562 - 569
  • [26] Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients
    Biagi, M.
    Badowski, M. E.
    Chiampas, T.
    Young, J.
    Patel, M.
    Vaughn, P.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (08) : 766 - 772
  • [27] Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection
    Huang, Y-S
    Lee, C-H
    Lee, Y-T
    Sun, H-Y
    Liou, B-H
    Yang, C-J
    Liu, C-E
    Tang, H-J
    Lin, S-P
    Cheng, C-Y
    Cheng, S-H
    Lu, P-L
    Ho, M-W
    Huang, S-H
    Tsai, H-C
    Hung, C-C
    HIV MEDICINE, 2019, 20 : 292 - 293
  • [28] A comparison between tenofovir/emtricitabine/elvitegravir/cobicistat and dolutegravir-based three-drug regimens as switch strategies for virologically controlled, HIV-infected patients
    Baldin, Gianmaria
    Borghetti, Alberto
    Capetti, Amedeo
    Sterrantino, Gaetana
    Rusconi, Stefano
    Latini, Alessandra
    Giacometti, Andrea
    Cossu, Maria Vittoria
    Colafigli, Manuela
    Micale, Mariangela
    Veloci, Sara
    Lombardi, Francesca
    De Marco, Ramona
    Emiliozzi, Arianna
    De Luca, Andrea
    Di Giambenedetto, Simona
    Madeddu, Giordano
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [29] Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
    Nadia Valin
    Laurent Fonquernie
    Anne Daguenel
    Pauline Campa
    Theresita Anthony
    Marguerite Guiguet
    Pierre Marie Girard
    Marie Caroline Meyohas
    BMC Infectious Diseases, 16
  • [30] Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
    Valin, Nadia
    Fonquernie, Laurent
    Daguenel, Anne
    Campa, Pauline
    Anthony, Theresita
    Guiguet, Marguerite
    Girard, Pierre Marie
    Meyohas, Marie Caroline
    BMC INFECTIOUS DISEASES, 2016, 16
12345